Registered title, quoted from ClinicalTrials.gov
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06439771, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,.
Inclusion criterion 3
Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system [Version 8]) who are not candidates for curative surgery or radiotherapy.
Inclusion criterion 2
Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.
Inclusion criterion 5
Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
Inclusion criterion 8
Have prior treatment with an agent targeting HER3.
Exclusion criterion 1
Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
Exclusion criterion 5
Have any other primary malignancy within 5 years prior to the first dose of study drug.
Exclusion criterion 19
Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Inclusion criterion 6
Patients with human immunodeficiency virus (HIV) infection.
Exclusion criterion 17
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Exclusion criterion 18
Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.
Exclusion criterion 22
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06439771, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
- Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system [Version 8]) who are not candidates for curative surgery or radiotherapy.
- Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,.
- Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression.
- Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.
- Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Have Adequate organ and bone marrow function within 7 days prior to the first dose.
- Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
- Have a expected survival ≥ 3 months.
- Have ability and willingness to comply with protocol-specified visits and procedures.
Exclusion Criteria:
- Have prior treatment with an agent targeting HER3.
- Have prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
- Have been enrolled in another clinical study concurrently unless it is an observational clinical study or in the follow-up phase of an interventional study.
- Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
- Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
- Have prior allogeneic bone marrow transplant or prior solid organ transplant.
- Have received treatment with systemic steroids.
- Have received any live vaccine within 4 weeks prior to the first dose of study drug or intend to receive a live vaccine during the study.
- Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
- Brain metastases with the exceptions.
- Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
- Have clinically significant concomitant pulmonary diseases.
- Have a diagnosis of Gilbert's syndrome.
- Have pleural effusion, abdominal effusion.
- Have a history of gastrointestinal perforation and or fistula within 6 months prior to the first dose.
- Have serious infection.
- Patients with human immunodeficiency virus (HIV) infection.
- Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Have any other primary malignancy within 5 years prior to the first dose of study drug.
- Have unresolved toxicities from prior anticancer therapy.
- Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
- Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.
Quoted from ClinicalTrials.gov, NCT06439771, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06439771, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.